Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director John Schmid sold 20,645 shares of AnaptysBio stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares of the company’s stock, valued at approximately $1,774,310.42. The trade was a 39.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

AnaptysBio Trading Up 4.9%

ANAB traded up $2.78 during trading on Thursday, reaching $59.51. 73,440 shares of the company were exchanged, compared to its average volume of 547,658. AnaptysBio, Inc. has a 52 week low of $15.40 and a 52 week high of $68.39. The firm has a 50 day moving average of $55.88 and a 200 day moving average of $44.33. The stock has a market cap of $1.71 billion, a P/E ratio of -114.72 and a beta of 0.40.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.89 by $0.69. The business had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. As a group, analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has initiated a stock buyback program on Friday, March 27th that allows the company to repurchase $100,000.00 billion in shares. This repurchase authorization allows the biotechnology company to buy up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the period. Invesco Ltd. boosted its stake in AnaptysBio by 192.6% in the 4th quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock worth $6,012,000 after purchasing an additional 81,625 shares during the period. Mackenzie Financial Corp purchased a new stake in shares of AnaptysBio in the fourth quarter worth approximately $1,166,000. XTX Topco Ltd increased its stake in AnaptysBio by 113.3% in the 4th quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock valued at $1,873,000 after buying an additional 20,526 shares during the period. Finally, nVerses Capital LLC acquired a new stake in shares of AnaptysBio during the 4th quarter valued at $215,000.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ANAB shares. Wedbush upped their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Truist Financial upgraded shares of AnaptysBio to a “hold” rating in a report on Wednesday, March 25th. Stifel Nicolaus increased their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. UBS Group raised their target price on shares of AnaptysBio from $70.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Finally, Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.10.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.